BioNTech SE (NASDAQ:BNTX) Receives $142.72 Consensus Price Target from Analysts

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seventeen brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $142.72.

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group raised their price objective on BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research note on Wednesday, November 27th. Berenberg Bank began coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a "buy" rating and a $130.00 price objective on the stock. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and upped their target price for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Truist Financial initiated coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. Finally, BMO Capital Markets reissued an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares in the last quarter. Planning Capital Management Corp increased its stake in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after acquiring an additional 450 shares during the period. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE bought a new position in BioNTech during the fourth quarter worth about $90,000. Finally, GAMMA Investing LLC boosted its holdings in BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

Remove Ads

BioNTech Price Performance

BNTX stock traded down $3.43 during trading hours on Friday, hitting $105.35. 1,159,581 shares of the stock traded hands, compared to its average volume of 789,512. The stock has a 50-day simple moving average of $116.91 and a 200 day simple moving average of $112.93. The company has a market cap of $25.26 billion, a P/E ratio of -50.17 and a beta of 0.30. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the firm posted $1.90 EPS. The business's revenue for the quarter was down 19.5% on a year-over-year basis. Equities analysts forecast that BioNTech will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.